Noble Financial initiated coverage on shares of Nutriband (NASDAQ:NTRB – Get Free Report) in a report issued on Wednesday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $13.00 price target on the stock. Noble Financial’s target price would suggest a potential upside of 31.31% from the company’s current price.
Nutriband Stock Performance
NASDAQ:NTRB opened at $9.90 on Wednesday. The stock has a 50 day simple moving average of $4.49 and a 200 day simple moving average of $5.41. The stock has a market cap of $109.99 million, a P/E ratio of -13.94 and a beta of 0.99. Nutriband has a 1-year low of $2.22 and a 1-year high of $11.78. The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.01.
Nutriband (NASDAQ:NTRB – Get Free Report) last announced its earnings results on Tuesday, December 3rd. The company reported ($0.12) earnings per share (EPS) for the quarter. Nutriband had a negative net margin of 338.51% and a negative return on equity of 54.49%.
About Nutriband
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
Featured Articles
- Five stocks we like better than Nutriband
- What is the Euro STOXX 50 Index?
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- How to Effectively Use the MarketBeat Ratings Screener
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- How to Short a Stock in 5 Easy StepsÂ
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.